INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Unicycive Therapeutics (UNCY) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm

Core Points - Holzer & Holzer, LLC has initiated a shareholder class action lawsuit against Unicycive Therapeutics, alleging that the company made materially false and misleading statements regarding its FDA manufacturing compliance and the regulatory prospects of its OLC NDA [1] - The lawsuit claims that Unicycive overstated its readiness to meet FDA requirements and the likelihood of regulatory approval for its product [1] - Shareholders who purchased Unicycive shares between March 29, 2024, and June 27, 2025, are encouraged to contact the law firm for more information regarding their legal rights [2] Legal Context - The deadline for shareholders to request to be appointed as lead plaintiff in the case is October 14, 2025 [3] - Holzer & Holzer, LLC is recognized as a top-rated securities litigation law firm and has a history of recovering significant amounts for shareholders affected by corporate misconduct [3]